Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) EBT Margin (2016 - 2025)

Historic EBT Margin for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to 760.14%.

  • Intellia Therapeutics' EBT Margin rose 6957700.0% to 760.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 774.19%, marking a year-over-year increase of 3586000.0%. This contributed to the annual value of 840.5% for FY2024, which is 4426400.0% up from last year.
  • According to the latest figures from Q3 2025, Intellia Therapeutics' EBT Margin is 760.14%, which was up 6957700.0% from 720.21% recorded in Q2 2025.
  • Intellia Therapeutics' 5-year EBT Margin high stood at 6647.52% for Q4 2023, and its period low was 23881.33% during Q3 2021.
  • Over the past 5 years, Intellia Therapeutics' median EBT Margin value was 780.83% (recorded in 2022), while the average stood at 1714.08%.
  • As far as peak fluctuations go, Intellia Therapeutics' EBT Margin tumbled by -237560400bps in 2021, and later skyrocketed by 231005000bps in 2022.
  • Intellia Therapeutics' EBT Margin (Quarter) stood at 621.69% in 2021, then fell by -24bps to 771.63% in 2022, then surged by 961bps to 6647.52% in 2023, then crashed by -115bps to 977.29% in 2024, then increased by 22bps to 760.14% in 2025.
  • Its last three reported values are 760.14% in Q3 2025, 720.21% for Q2 2025, and 674.83% during Q1 2025.